SS Innovations International Inc. (NASDAQ: SSII) reported record first-quarter 2026 financial results, with revenue surging 116.8% year over year to $11.1 million, driven by growing adoption of its SSi Mantra surgical robotic system. The company's installed base reached 194 SSi Mantra systems across 11 countries, and cumulative robotic procedures totaled nearly 9,750 during the quarter. Gross profit rose to $5.3 million from $1.1 million a year earlier, reflecting improved operational efficiency and higher procedure volumes.
The company's international expansion gained momentum with regulatory approvals in Sri Lanka, Kenya, Indonesia, and the Philippines during the quarter. These approvals expand market access in emerging healthcare markets, where demand for minimally invasive surgical technologies is rising. SS Innovations also completed the world's longest-distance robotic cardiac telesurgery, demonstrating the capabilities of its remote surgery platform and positioning the company as a leader in telesurgery innovation.
As of June 22, 2026, the cumulative number of multi-specialty procedures performed with the SSi Mantra reached 11,719, including 612 cardiac procedures, 175 telesurgeries, and 212 pediatric surgeries. Approximately 2,100 physicians have been trained on the system, which has been used for over 170 different types of procedures. This rapid adoption underscores the platform's versatility and clinical value across surgical specialties.
SS Innovations continues to pursue regulatory clearance in both the United States and Europe, which represent major growth opportunities. The company's focus on emerging markets, combined with its technological advancements in telesurgery, positions it to capture a significant share of the global surgical robotics market, expected to grow substantially in the coming years.
For more information, visit the company's website at www.SSInnovations.com.
InvestorWire, a platform for advanced press release syndication, distributed this content. For more details, see https://www.InvestorWire.com and the disclaimer at https://www.InvestorWire.com/Disclaimer.
